Bako Diagnostics

Founded in 2008, Bako Diagnostics is a forefront provider of diagnostic and therapeutic services, specializing in pathology of the lower extremity. With a comprehensive testing menu including ENFD Analysis, Mass Spectrometry, and Molecular Genetics, the company offers intelligence, not just information, to the podiatric medical community. It boasts an extensive network, covering over 200 million lives, including all five national health plans, and employs fully compliant patient-friendly billing policies. Over the past nine years, Bako Diagnostics has established itself as a primary source of educational sponsorship within the podiatric profession. The company's recent Private Equity Round investment in January 2016, led by Consonance Capital, underscores its potential for further growth and development in the healthcare industry. With a headquarters in the United States, Bako Diagnostics is dedicated to serving as a professional partner for disease diagnostics and management, embodying a commitment to diagnostic excellence and education. For more information, visit bakodx.com or call 855-422-5628.